Advertisement
Advertisement
September 10, 2026
IceCure’s ProSense Cryoablation System Approved in China
KEY TAKEAWAYS
- China’s NMPA has approved IceCure Medical Ltd.’s ProSense cryoablation system and associated cryoprobes as a class III medical device.
- The approval allows ProSense to be marketed in China in accordance with its approved registration.
- The liquid-nitrogen–based technology is designed to destroy benign and cancerous tumors by freezing.
September 10, 2026—IceCure Medical Ltd. announced that it has received approval for its ProSense cryoablation system and associated cryoprobes as a class III medical device from China’s National Medical Products Administration (NMPA). The minimally invasive cryoablation technology is intended to destroy tumors by freezing as an option to surgical tumor removal.
IceCure advised that the NMPA approval enables ProSense to be marketed in China in accordance with the approved registration.
The ProSense system, the company’s flagship technology, is marketed and sold worldwide for the indications cleared and approved to date, including in the United States, Europe, and Asia. IceCure’s liquid-nitrogen–based cryoablation therapy systems were developed for the destruction of both benign and cancerous tumors by freezing, with the primary focus areas being breast, kidney, bone, and lung cancer, stated the company.
Advertisement
Advertisement
